Advanced search
Publication Cover
Future Science OA Volume 8, 2022 - Issue 4
Submit an article Journal homepage
721
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Demography, Patterns of care, and Survival Outcomes in Patients With Salivary Duct Carcinoma: an Individual Patient Data Analysis of 857 Patients

Prashanth Giridhar1 Department of Radiation Oncology, Tata Medical Centre, Varanasi
,
Bhanu Prasad Venkatesulu2 Loyola University Chicago, Loyola University Medical Center &/or Edward Hines Jr., VA Hospital, Stritch School of Medicine, Department of Radiation Oncology, Cardinal Bernardin Cancer Center, Maywood, IL, 60153, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2541-2055
ORCID Icon,
Ryan Yoo2 Loyola University Chicago, Loyola University Medical Center &/or Edward Hines Jr., VA Hospital, Stritch School of Medicine, Department of Radiation Oncology, Cardinal Bernardin Cancer Center, Maywood, IL, 60153, USA
,
Pragathee V3 Department of Internal Medicine, Karpagam Faculty of Medical Sciences & Research, Coimbatore, Tamil Nadu, India
,
Goura K Rath4 Department of Radiation Oncology, All India institute of medical sciences, New Delhi, India
,
Supriya Mallick4 Department of Radiation Oncology, All India institute of medical sciences, New Delhi, India
,
Ashishdutt Upadhyay5 Department of Biostatics, All India Institute of Medical Sciences, New Delhi, India
&
Dennis Pai Chan2 Loyola University Chicago, Loyola University Medical Center &/or Edward Hines Jr., VA Hospital, Stritch School of Medicine, Department of Radiation Oncology, Cardinal Bernardin Cancer Center, Maywood, IL, 60153, USA
 show all
Article: FSO791 | Received 21 Apr 2021, Accepted 23 Feb 2022, Published online: 08 Mar 2022

References

  • JayaprakashV , MerzianuM , WarrenGWet al.Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck36(5), 694–701 (2014).
  • GilbertMR , SharmaA , SchmittNCet al.A 20-year review of 75 cases of salivary duct carcinoma. JAMA Otolaryngol. Head Neck Surg.142(5), 489–495 (2016).
  • JohnstonML , HuangSH , WaldronJNet al.Salivary duct carcinoma: treatment, outcomes, and patterns of failure. Head Neck38(Suppl. 1), E820–E826 (2016).
  • BakstRL , SuW , OzbekUet al.Adjuvant radiation for salivary gland malignancies is associated with improved survival: a National Cancer Database analysis. Adv. Radiat. Oncol.2(2), 159–166 (2017).
  • XuB , DoganS , HaroonAl Rasheed MR , GhosseinR , KatabiN. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Hum. Pathol.93, 30–36 (2019).
  • DalinMG , DesrichardA , KatabiNet al.Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin. Cancer Res.22(18), 4623–4633 (2016).
  • DalinMG , WatsonPA , HoAL , MorrisLG. Androgen receptor signaling in salivary gland cancer. Cancers9(2), 17 (2017).
  • SygutD , BienS , ZiolkowskaM , SpornyS. Immunohistochemical expression of androgen receptor in salivary gland cancers. Pol. J. Pathol.59(4), 205–210 (2008).
  • YeohCC , DababN , RigbyEet al.Androgen receptor in salivary gland carcinoma: a review of an old marker as a possible new target. J. Oral Pathol. Med.47(7), 691–695 (2018).
  • Van BoxtelW , LocatiLD , vanEngen-van Grunsven ACH, PALGA Groupet al.Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. Eur. J. Cancer110, 62–70 (2019).
  • ViscusePV , PriceKA , GarciaJJ , Schembri-WismayerDJ , ChintakuntlawarAV. First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma-a retrospective study. Front. Oncol.9, 701 (2019).
  • BoonE , van BoxtelW , ButerJet al.Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands. Head Neck40(3), 605–613 (2018).
  • CorrêaTS , MatosGDR , SeguraM , DosAnjos CH. Second-line treatment of HER2-positive salivary gland tumor: ado-trastuzumab emtansine (T-DM1) after progression on trastuzumab. Case Rep. Oncol.11(2), 252–257 (2018).
  • FirwanaB , AtassiB , HasanR , HasanN , SukariA. Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: case report and review of the literature. Avicenna J. Med.2(3), 71–73 (2012).
  • TakahashiH , TadaY , SaotomeTet al.Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J. Clin. Oncol.37(2), 125–134 (2019).
  • AminiA , WaxweilerTV , BrowerJVet al.Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the National Cancer Data Base. JAMA Otolaryngol. Head Neck Surg.142(11), 1100–1110 (2016).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.